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Abstract
The toxicity of antineoplastic drugs is well documented. Many are known or suspected human 
carcinogens where no safe exposure level exists. Authoritative guidelines developed by 
professional practice organizations and federal agencies for the safe handling of these hazardous 
drugs have been available for nearly three decades. As a means of evaluating the extent of use of 
primary prevention practices such as engineering, administrative and work practice controls, 
personal protective equipment (PPE), and barriers to using PPE, the National Institute for Safety 
and Health (NIOSH) conducted a web survey of health care workers in 2011. The study 
population primarily included members of professional practice organizations representing health 
care occupations which routinely use or come in contact with selected chemical agents. All 
respondents who indicated that they administered antineoplastic drugs in the past week were 
eligible to complete a hazard module addressing self-reported health and safety practices on this 
topic. Most (98%) of the 2069 respondents of this module were nurses. Working primarily in 
hospitals, outpatient care centers, and physician offices, respondents reported that they had 
collectively administered over 90 specific antineoplastic drugs in the past week, with carboplatin, 
cyclophosphamide, and paclitaxel the most common. Examples of activities which increase 
exposure risk, expressed as percent of respondents, included: failure to wear nonabsorbent gown 
with closed front and tight cuffs (42%); intravenous (I.V.) tubing primed with antineoplastic drug 
by respondent (6%) or by pharmacy (12%); potentially contaminated clothing taken home (12%); 
spill or leak of antineoplastic drug during administration (12%); failure to wear chemotherapy 
gloves (12%); and lack of hazard awareness training (4%). The most common reason for not 
wearing gloves or gowns was “skin exposure was minimal”; 4% of respondents, however, 
reported skin contact during handling and administration. Despite the longstanding availability of 
safe handling guidance, recommended practices are not always followed, underscoring the 
importance of training and education for employers and workers.
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INTRODUCTION
Antineoplastic drugs, also known as chemotherapy, cytotoxic, and oncology drugs, are used 
extensively in health care to treat cancer patients and are increasingly being used to treat 
arthritis, multiple sclerosis, and other noncancer medical conditions. Most antineoplastic 
drugs are hazardous drugs.(1) In the United States, an estimated 8 million health care 
workers are potentially exposed to hazardous drugs.(2) This figure is expected to increase in 
years to come as new cancer cases are on the rise due to an aging population and as these 
drugs find wider use for treating non-cancer-related medical conditions.(3)
The health risks associated with exposure to antineoplastic drugs are well documented. 
Patients undergoing chemotherapy treatment have developed secondary malignancies, 
leukemia being the most frequently observed, although bladder cancer and lymphoma have 
also been reported.(4–6) Acute health effects associated with occupational exposure include 
skin rashes, sore throat, chronic cough, dizziness, headache, eye irritation, hair loss, and 
allergic reactions.(7,8) Reproductive studies of female health care workers exposed to these 
drugs have shown infertility, miscarriage, birth defects, and other adverse pregnancy 
outcomes.(9,10) Oncology nurses exposed to chemotherapeutic drugs have increased risk of 
leukemia and other cancers.(10) An increased frequency of genotoxicity biomarkers 
including chromosomal aberrations were reported in health care workers who handle 
chemotherapy drugs.(11,12)
When health risks to exposed workers became a recognized safety concern, professional 
practice organizations(13,14) and government agencies(15,16) published guidelines for the safe 
handling of hazardous drugs. The guidelines cover specific methods and equipment for 
protecting workers who handle hazardous chemotherapy drugs throughout their life cycle in 
the health care setting—from shipping/receiving, transport and distribution, compounding, 
administration, and waste disposal. These guidelines are generally consistent with respect to 
primary prevention measures and application of a hierarchy of control technologies to 
mitigate workplace hazards.(17) The hierarchy specifies that unless the hazard can be 
eliminated or substituted by a substance less toxic (which is not feasible with respect to 
antineoplastic drugs), exposure controls should be systematically implemented in the 
following decreasing order of efficacy: 1) engineering controls, 2) administrative controls, 
3) work practice controls, and 4) personal protective equipment (PPE). Examples of 
engineering controls include closed-system transfer devices (CSTDs) and luer-lock fittings. 
Examples of administrative controls include training and education, hazard communication, 
medical surveillance, and other policies that reduce exposure. Examples of work practice 
controls include cleaning spilled chemicals immediately and keeping supplies such as 
absorbent pads readily available.
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Regarding PPE, a standard or universal precautions approach should be applied for all 
hazardous chemotherapy drugs and formulations, as the inherent toxicity of the drug is 
unaffected by the formulation used. Also, new investigational drugs used to treat cancer and 
other serious diseases possessing one of the six characteristics which define a hazardous 
drug should be handled as such.(15) When handling hazardous chemotherapy drugs where 
there is no known permissible exposure level, prudence dictates that exposure be kept as low 
as is achievable.
Since the first set of guidelines was published, several survey-based studies of nurses have 
been conducted to characterize exposure control practices during various chemotherapy 
handling activities, including administration.(18–26) Each of these studies reported on use of 
PPE, primarily gloves and gowns, and to a lesser extent on eye protection and respirators. 
Specialized training, awareness of hazardous drug programs, skin contact, medical 
monitoring, reasons for PPE disuse, and comparison of selected practices by work setting 
were sporadically reported. Recent studies(27,28) have reported on PPE full ensemble use, in 
addition to other practices such as double gloving, gown re-use, and availability of written 
policies and procedures and spill kits. The latter study(28) is one of the first to evaluate 
possible correlations between organizational factors and use of precautionary measures, 
although a prior study(29) examined possible relationships between organizational structures/
processes of care and self-reported exposure to chemotherapy.
The primary purpose of this study is to describe chemotherapy drug administration practices 
and extent of use of exposure controls, and impediments to PPE use by health care workers 
who administer antineoplastic drugs. This study is distinct from previous studies—it has a 
national reach and encompasses a large number of respondents and workplaces. Study 
findings can be used to raise awareness among employers and health care workers regarding 
hazards, safe handling guidelines, and use of exposure controls.
METHODS
Survey Methodology
The National Institute for Occupational Safety and Health (NIOSH) Health and Safety 
Practices Survey of Healthcare Workers is an anonymous, multi-module, web-based survey 
that was conducted January 28 through March 29, 2011. The study population primarily 
included members of professional practice organizations representing health care 
occupations which routinely use or come in contact with selected chemical agents. Practices 
around administration of antineoplastic drugs were addressed by one of seven hazard 
modules which was targeted to professional organizations representing oncology nurses, 
hematology/oncology nurses, and infusion nurses. Practices around compounding of 
chemotherapy drugs were addressed in a separate hazard module and will be reported 
elsewhere. Information on overall methods used in the development and testing of the 
survey instrument, web survey design and functionality, survey population, survey 
implementation, respondent characteristics, and other information including strengths and 
limitations of the overall survey have been described elsewhere.(30)
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The hazard module addressing administration of antineoplastic drugs contained 49 
questions. The format of the questions varied, including multiple choice, multi-part, yes/no, 
and numeric. Many of the questions addressing exposure controls included specific 
engineering controls, administrative controls, and PPE that were recommended in guidelines 
available at the time of the survey.(15,16,31,32) Topic areas and content of selected questions 
are presented in Table I.
Respondents were asked to select from a list of 92 antineoplastic drugs and 7 monoclonal 
antibodies (mAbs) those that they had administered in the past 7 calendar days. Most of the 
antineoplastic drugs were from the “2010 NIOSH List of Antineoplastic and Other 
Hazardous Drugs in Health Care Settings”(1) with the remaining identified from literature/
Internet searches. For this question as well as others where the choices were not exhaustive, 
respondents could mark “other” and type in a response. These were reviewed and 
determined if they a) fit into one of the existing categories, b) were a valid other response, or 
c) were unrelated to the question, i.e., general notes about the survey. Responses were 
recoded, or left as “other” in the case of b), to reflect this determination.
The modular survey was programmed to present, based on screening questions, the most 
relevant hazard module first, then the core module, and then a second hazard module, if 
indicated. Respondents were presented with not more than two hazard modules. It was 
possible for respondents to complete the module on administration of antineoplastic drugs 
and not the core module. In those cases, demographic information is unavailable.
Data Analysis
Data were analyzed using SAS 9.3 (SAS Institute, Inc., Cary N.C.). Simple frequencies and 
prevalences are presented. Respondents who only administered mAbs (n = 23) were 
excluded from the analyses because mAbs are not classified as hazardous drugs and lack 
authoritative guidelines for their safe use. Results include responses to questions on 
administration of antineoplastic drugs and selected questions in the core module that 
describe respondent demographic, employer, and occupation characteristics for those 
respondents. Age was estimated by subtracting respondents’ year of birth from the year the 
survey took place, 2011. Neither exact birthdate nor age were asked.
Human Subjects Review Board
The NIOSH Human Subjects Review Board determined that the activities in this project 
were surveillance and did not meet the criteria of research according to 45 CFR 46.1101(b) 




There were 2069 respondents who completed the hazard module addressing administration 
of antineoplastic drugs. Of these, 1954 (94%) completed the core module and thus could be 
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characterized by demographic and other descriptive information. Demographic 
characteristics are presented in Table II. These respondents were predominately female, 
Caucasian, 41 to 55 years of age, and had at least a bachelor’s degree.
Nurses represented nearly all respondents and most categorized themselves as oncology 
nurses, hematology/oncology nurses, and infusion/I.V. therapy nurses. Nearly 7 of every 10 
respondents had 6 or more years of experience in their current occupation, and almost half 
reported working with their current employer for more than 10 years. One in 5 respondents 
was a member of a labor union.
Most respondents worked in hospitals with nearly all others working in ambulatory health 
care settings. Nearly 7 in 10 respondents worked for employers with >100 employees. Over 
half of respondents’ employers were non-profit. Respondents worked in all U.S. 
geographical regions with the South having the highest representation, and nearly two-thirds 
of their employers were located in large cities.
Administration Characteristics
More than half of the respondents administered antineoplastic drugs for 11 years or more 
(Table III). Respondents were evenly distributed among the number of days they 
administered antineoplastics up to 5 days in the past 7 calendar days, with 6 or 7 days being 
highly uncommon. Nearly half of the respondents administered 4 or fewer treatments in the 
past 7 calendar days and a small fraction administered more than 40 treatments. Most 
respondents reported that the number of treatments was no different than usual. Three-
quarters of respondents reported that their treatments were in liquid form only; treatments 
consisting of a combination of liquids and tablets/capsules were less common (Table III).
Respondents reported a number of different work settings where they administered 
antineoplastic drugs to patients. The areas most frequently reported included outpatient 
centers/ clinics and patients’ or treatment rooms in hospitals (Table II).
Table IV presents the top 20 antineoplastic drugs by decreasing percent of respondents who 
administered them to patients during the past 7 calendar days. Carboplatin and 
cyclophosphamide represented the two most commonly administered drugs; slightly over 
half of the respondents reported that they had administered them. The median number of 
chemotherapy drugs administered during the past week was 7 (range: 1 to 74). Only 4 of the 
92 antineoplastic drugs on the list were not selected including alitretinoin, 
aminoglutethimide, motexafin gadolinium, and toremifene. Nearly 6% of respondents 
reported that they had administered “other” antineoplastic drugs and “investigational 
compounds (not yet named).”
Training and Awareness of Employer Procedures and National Guidelines for Safe 
Handling of Antineoplastic Drugs
Most respondents reported that they had received training on the safe handling of 
antineoplastic drugs. Of those who received training, over a third reported that it had been 
more than 12 months ago (Table V). With respect to continuing education courses 
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addressing safe handling of chemotherapy drugs, courses offered by the Oncology Nursing 
Society (ONS) were completed in the highest proportion by respondents.
Some respondents reported that their employer either did not have—or they themselves were 
not aware if they had—procedures addressing safe chemotherapy administration. Regarding 
awareness of national safe handling guidelines, respondents were asked to choose their level 
of familiarity with ONS, American Society of Health-System Pharmacists (ASHP), NIOSH, 
and Occupational Safety and Health Administration (OSHA) guidelines. Nearly three-
quarters of respondents were “very” familiar with ONS guidelines, nearly half with OSHA 
guidelines, and a lesser extent with NIOSH and ASHP guidelines.
Adherence to Safe Handling Guidelines
Selected work practices were evaluated to determine the extent to which precautionary 
guidelines were being used to minimize exposures. Frequency distributions of responses 
primarily focus on the percent of respondents who are not fully adhering to recommended 
practices.
I.V. Tubing Priming Practices—When asked how liquid chemotherapy drugs were 
delivered from the pharmacy, more than one of every 10 respondents reported that the I.V. 
tubing was primed with chemotherapy drug (Table VI). Four of every 10 respondents 
reported that they always or sometimes primed I.V. tubing before administering 
chemotherapy to patients. Priming with the chemotherapy drug was reported by 6% of all 
survey respondents, although priming with a non-drug containing fluid such as saline was a 
more common practice.
Crushing Tablets and Opening Capsules of Chemotherapy Drugs—The practice 
of crushing tablets and/or opening capsules of chemotherapy drugs was reported by more 
than one of every 10 respondents. When asked to select all of the locations where these 
activities were performed, a third of therespondents each reported bedside, clinical areas, 
and pharmacy (Table VI).
Use of Engineering Controls—Respondents handling liquid antineoplastic drugs were 
asked how often they used a CSTD, luer-lock fittings, and needleless systems during 
administration (Table VII). Over half of respondents reported they sometimes or never used 
a CSTD; however, needleless systems and luer-lock fittings were more widely used.
Precautionary Work Practices—Respondents were asked how often they utilized 
specific precautionary work practices relative to minimizing exposure to chemotherapy 
drugs (Table VII). Four of every 10 respondents sometimes or never used a plastic-backed 
absorbent pad under the injection site during administration. Over a quarter of respondents 
reported that they sometimes or never stored prepared chemotherapy drugs in an area 
restricted to authorized personnel when they had the opportunity to do so. Nearly one of 
every 10 respondents did not always wash their hands after removing gloves, and a smaller 
proportion did not always replace their gloves immediately when damaged or contaminated.
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Use of Personal Protective Equipment—Respondents were asked how often they 
wore specific types of PPE while administering chemotherapy drugs to patients (Table VII). 
Chemotherapy gloves were not always worn by nearly 1 of every 7 respondents. Some did 
not know whether the gloves they wore were chemotherapy gloves. Of those who reported 
wearing chemotherapy gloves, nearly 8 of every 10 respondents reported that they did not 
always wear two pairs (i.e., double glove). Nonabsorbent gowns with closed front and tight 
cuffs were not always worn by more than 4 of every 10 respondents. Much higher levels of 
disuse (sometimes/never use) were reported for eye/face protection, respirators, head covers, 
and shoe covers. Standard surgical masks were reportedly worn by 1 of every 5 respondents 
while administrating antineoplastic drugs, presumably for infection control.
Respondents who reported that they sometimes or never wore PPE were asked to select from 
a list all applicable reasons for not always wearing PPE while administering chemotherapy 
drugs. This information was obtained for chemotherapy gloves, nonabsorbent gowns (with 
closed front and tight cuffs), eye/ face protection, and respirators. The percents of 
respondents selecting each of nine reasons (excluding “other”) by type of PPE are presented 
in Table VIII. The most commonly reported reason for not wearing chemotherapy gloves 
was “skin exposure was minimal,” followed by “not provided by employer” and “not part of 
our protocol.” The most commonly reported reason for not wearing nonabsorbent gowns 
was “skin exposure was minimal” followed by “not part of our protocol” and “no one else 
who does this work uses them.” The three most commonly reported reasons for not always 
wearing eye/face protection and respirators were in the same rank order: “not part of our 
protocol,” “exposure was minimal,” and “an engineering control was being used.”
Took Home Potentially Contaminated Clothing—When respondents were asked if 
they took home any clothing that came into contact with chemotherapy drugs, 12% 
responded affirmatively and another 11% did not know (Table VI).
Glove Use: Activities Where Cross-Contamination May Occur (Done While 
Wearing Gloves That Were Used While Administering Antineoplastic Drugs)—
Respondents were asked if they performed specific activities while wearing gloves that had 
been used to administer antineoplastic drugs. The most common activity reported by 6 of 
every 10 respondents was “touch I.V. pump or bed controls.” Other reported activities 
included: “touch waste basket,” “use pens/pencils,” “touch door knobs, cabinets, or 
drawers,” “use computer or calculator,” “handle files or charts,” among others (Table VI).
Re-Use of Gloves—The practice of re-using gloves (i.e., removing and later putting back 
on gloves that had been worn while administering chemotherapy drugs) was infrequent, but 
still reported by 1% of respondents (n = 1961) (Table VI).
Skin Contact and Sharps Injury—Eighty-four (4.2%) respondents who handled (liquid 
and solid) chemotherapy drugs in the past 7 days reported that their skin came in direct 
contact with these drugs. Twenty-seven (1.4%) respondents who handled liquid 
chemotherapy drugs reported that their skin was punctured by a sharp in the past 12 months 
while administering a liquid antineoplastic drug (data not shown).
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Number of Spills by Quantity, Cause of Spill, and Availability of Spill 
Response Kits—Twelve percent (12%) of respondents who handled liquid chemotherapy 
drugs reported experiencing a spill/leak during administration in the past week (Table IX). 
The most common cause, reported by over 70% of respondents reporting a spill, was 
“attaching, injecting, or detaching from I.V. line.” Other causes in decreasing order of 
prevalence included: bad connection/leak, equipment malfunction, drawing up or expelling 
air from syringe, and excessive pressure in vial. Respondents who reported a spill were also 
asked whether or not they had experienced spills/leaks of “less than 5 ml” or “5 ml or more” 
and, if so, define for each amount the number as “1–2 spills,” “3–5 spills,” or “more than 5 
spills.” More respondents reported spills/leaks of less than 5 ml than those of 5 ml or more. 
Of those reporting a spill, nearly 8 of every 10 reported spills of less than 5 ml and 1 of 
every 10 reported spills of 5 ml or more. Multiple spill episodes during the past week were 
also reported. Nearly one of every 10 respondents reporting spills/leaks indicated that they 
were not always cleaned up. Some respondents reported that hazardous drug spill kits were 
either not available at work or they did not know if they were or not.
Medical Surveillance and Exposure Monitoring—A medical surveillance program, 
as defined in the survey, may include work history, physical exam, blood, and/or urine tests. 
Most (77%) respondents (n = 1987) reported that their employer does not provide a medical 
surveillance program or that they did not know whether their employer offered such a 
program or not. Some (19%) respondents reported participating in a medical surveillance 
program, and few (4%) reported that their employer offered such a program but they do not 
participate.
Nine of 10 respondents reported that exposure monitoring (e.g., air sampling, wipe 
sampling) either had not been conducted or they did not know whether it had been 
conducted in the last 12 months. Not even 1 of every 10 respondents reported that exposure 
monitoring had been conducted during this period.
DISCUSSION
This study represents one of the largest surveys of health care workers who administer 
antineoplastic drugs, with nearly 2100 respondents, mostly nurses, completing the hazard 
module addressing administration practices. The primary purpose of this hazard module was 
to describe the self-reported use of safe handling precautions during administration of 
chemotherapy drugs and to better understand impediments to PPE use which was minimally 
assessed in previous studies.
The survey results indicate that authoritative guidelines for the safe handling of 
chemotherapy drugs are not being universally followed. Questions addressing impediments 
to using exposure controls focused solely on PPE. Commonly reported reasons for not 
wearing requisite PPE (e.g., gloves and gowns) during administration suggest that there is a 
perception among respondents that chemotherapy drugs pose a minimal exposure risk. They 
also suggest that employers may be unaware of the adverse health risks of these highly toxic 
drugs, based on the following responses: “not part of our protocol” and “not provided by 
employer.” Although respondents were not asked why recommended engineering and 
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administrative controls were not used, the perceived minimal exposure risk may have played 
a role in their decision not to use them.
OSHA recommends that workers who handle hazardous drugs receive information and 
training at the time of initial assignment and annually thereafter on the hazards and means to 
control exposures.(16) The survey results show deficiencies related to the lack/infrequency of 
training, awareness of employer procedures, and awareness of national safe handling 
guidelines.
Other examples of breaches in safe work practices concerned the incomplete adoption of 
engineering controls including CSTDs, luer-lock fittings, and needleless systems. Nearly 
half of the respondents reported that they never used a CSTD possibly because they are 
relatively costly and require user training. Not always using luer-lock fittings, which are less 
prone to accidental separation than friction fittings, increases the likelihood of leaks at 
connections and potential exposure to chemotherapy drugs. Likewise, not always using 
needleless I.V. systems increases the likelihood of sharps injuries and potential exposure to 
chemotherapy drugs. In fact, 27 respondents reported that their skin was punctured by a 
sharp while administering chemotherapy drugs to patients.
Other work practices that placed study participants at risk of exposure included priming of 
I.V. tubing with chemotherapy drugs. OSHA specifies that drug administration sets (i.e., 
I.V. line) should be assembled and primed with a non-drug containing fluid, or a back-flow 
closed system (i.e., CSTD) should be used.(16) Priming with chemotherapy drug may cause 
the drug to drip at the end of the tube resulting in the greatest risk of releasing the 
chemotherapy drug into the work area. However, despite these safe handling guidelines, 
respondents reported both receiving I.V. lines primed with chemotherapy drugs from the 
pharmacy and that they themselves used the chemotherapy drug to prime the I.V. lines. 
Other examples of work practices that may increase the likelihood of exposure to 
chemotherapy drugs and/or contamination of work areas include not washing hands 
immediately after removing gloves post-administration, crushing tablets and/or opening 
capsules in unrestricted areas such as at the patient’s bedside and clinical areas, touching 
various objects in the work area while wearing gloves that had been used to administer 
chemotherapy drugs, and taking home clothing that came into contact with chemotherapy 
drugs.
In their safe handling guidelines, ONS, ASHP, NIOSH, and OSHA stipulate that double 
gloves and nonabsorbent gowns with closed front and tight cuffs should always be worn 
during administration of chemotherapy drugs. However, only 85% of respondents reported 
that they always wore (single) chemotherapy gloves, and double gloves were reportedly 
always worn by only 18% of respondents. These findings are consistent with recent studies 
reporting 76% to 99% use of single gloves and 15% to 49% use of double 
gloves.(26–28) Gowns were worn less frequently than gloves. Fewer than 6 of every 10 
respondents reported that they always wear gowns, which is within the range (51% to 75%) 
reported in recent studies.(26,27) The most commonly reported reason for not always wearing 
chemotherapy gloves and gowns was “exposure was minimal.” However, skin contact with 
antineoplastic drugs was not inconsequential, and was reported by 84 respondents during the 
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past week. The other top reasons “not provided by employer” and “not part of our protocol” 
suggest that employers may not be aware of the risks of exposure to chemotherapy drugs.
Spills/leaks of liquid antineoplastic drugs during administration were not uncommon, 
reported by more than 1 of every 10 respondents. Small spills (<5 ml) were more frequently 
reported than large spills. The most common causes of leaks were: attaching, detaching, 
making injections into I.V. line; bad connection; and equipment malfunction. Some 
respondents reported that spills or leaks were not always cleaned up. ASHP recommends 
that hazardous drug spill kits be available in all areas where hazardous chemotherapy drugs 
are handled and administered. A small percentage of respondents reported that spill kits 
were unavailable or they did not know whether they were, a finding similar to another 
survey.(27)
OSHA and NIOSH recommend medical surveillance of workers potentially exposed to 
chemotherapy drugs to prevent occupational injury or disease. Most respondents did not 
participate in a medical surveillance program; the majority reported that their employer did 
not have a program, were unaware whether their employer had a program, or decided not to 
participate. The percent of respondents participating in a medical surveillance program 
(19%) was markedly lower than reported (46%, 47%) in previous surveys.(24,27)
A recent survey has shown that organizational factors including improved positive 
workplace safety climate, reduced patient work load (i.e., fewer number of patients per day), 
and fewer barriers to using PPE play an important role relative to the use of precautionary 
measures.(28) Similar findings were reported in another survey where the likelihood of 
chemotherapy drug exposure decreased when nurses reported adequate staffing, resources, 
and favorable working conditions.(29)
Several limitations apply to this survey. Since the survey sample was targeted at members of 
professional practice organizations, findings reflect the experiences and practices of the 
respondents and are not generalizable to all health care workers or to all members of each of 
the participating professional organizations. Another limitation is that the survey was only 
available to members with email addresses and Internet access. Survey participants who 
have the resources that allow them to belong to a professional organization may be more 
likely to be farther along in their career, better paid, more educated, and more aware of 
health and safety issues. A response rate cannot be calculated because the invitation email 
specified the chemical agents under study, including antineoplastics, and that eligibility was 
based on whether invitees had used antineoplastic drugs on the job; it is unknown who 
decided not to participate because they did not use antineoplastic drugs versus those who 
used them but decided not to participate for other reasons.
Demographic information was not available for respondents who elected not to participate in 
the core module. Information on barriers to using engineering controls and proper work 
practices, as well as exposure controls used during handling of chemotherapy waste, was not 
collected in this study and should be evaluated in future studies. Although survey data are 
self-reported and not validated by observation or other means, the relatively large numbers 
of respondents reporting lapses in safe working practices cannot be ignored.
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Antineoplastic drugs represent one of the most toxic classes of chemical agents used in 
health care. Yet, despite this distinction, and the fact that sufficient evidence exists 
concerning their harmful effects on exposed health care workers, the data from this survey 
show that nurses and other health care workers are not universally adhering to longstanding 
safe handling guidelines, placing themselves and even family members at risk of exposure. 
The most commonly reported barriers associated with lapses in the use of protective gloves 
and gowns suggest that there is a perception that exposures are inconsequential or so rare 
that they do not justify their use. Better risk communication is needed to ensure that 
employers and health care workers are fully aware of the hazards and precautionary 
measures to minimize exposures to these highly toxic drugs.
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TABLE I
Survey Instrument Topic Areas and Content of Selected Questions
Topic Area
Training
    Frequency (more or less than 12 months ago)
    Source (ONS, APHON courses, other)
Awareness of employer safe administration procedures and national safe handling guidelines
Antineoplastic drugs administered (list of 92 specific drugs)
Administration practices
    Number of days administering chemotherapy in the past 7 calendar days
    Number of treatmentsA in the past 7 calendar days
    How number of treatmentsA compared to usual
    Locations where chemotherapy was administered
    Frequency of use of selected exposure controls
Physical form (liquid, tablet/capsule) of chemotherapy
I.V. tubing priming practices
    Whether or not tubing was primed by pharmacy and, if so, type of priming solutionB
    Whether or not tubing was primed by respondent and, if so, type of priming solutionB
    Frequency of priming by respondent
Spills
    Number, quantity, and cause of spills
    Availability of spill response kits
    Spill cleanup practices
Skin contact/puncture during administration
Use of PPE
    Chemotherapy gloves (single and double gloves)
    Nonabsorbent gowns with closed front and tight cuffs
    Eye/face protection (e.g., goggles/face shields)
    RespiratorsC
    Shoe and head covers
Use of surgical masks
Barriers to using PPE (except for shoe and head covers)
Activities performed while wearing chemo gloves that had been used to administer chemotherapy drugs




One treatment equals one or more chemotherapy drugs administered to one patient during one therapy session.
B
Chemotherapy drug or non-drug containing fluid.
C
Includes N95 filtering facepiece respirator, surgical N95 respirator, half-facepiece air-purifying (APR) respirator with chemical cartridge(s), and 
powered air-purifying respirator (PAPR) with chemical cartridge(s), and other.


















    Male 4
    Female 96
Race (1896)B
    Caucasian 92
    African American 4
    Asian 4
    Other 2
Ethnicity (1911)
    Hispanic 3
Age (1883)
    18–25 years 1
    26–40 years 18
    41–55 years 47
    56–70 years 33
    >70 years 1
Education (1903)C
    Grade 12 or less 1
    Vocational certificate 2
    Associate’s degree 26
    Bachelor’s degree 51
    Master’s degree 19
    Doctoral degree/Professional degree+ 2
Occupation (1943)
    Nurse 99
     Nursing specialty (1911)
     Oncology Nurse 39
     Hematology/Oncology Nurse 32
     Infusion/I.V. Therapy Nurse 9
     Clinical Nurse Specialist 4
     Other specific nurse specializations (26 with <3% each) 16
   Other 1
Time in Current Occupation (1935)
    <1 year 2
    1–5 years 20
    6–10 years 20
    11–20 years 31
    >20 years 27
Percent of Time Spent in Direct Patient Care (1938)
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Characteristic (nA) Percent
    76–100% 69
    51–75% 14
    26–50% 9
    1–25% 8
    No direct patient care 0
Time with Current Employer (1940)B
    <1 year 5
    1–5 years 27
    6–10 years 20
    11–20 years 25
    >20 years 22
Member of a Labor Union (1917)
    Yes 19
    No 81
Employer Industry Category (1939)
    Ambulatory health care services 37
    Hospital 61
    Nursing and residential care 1
    Social assistance/services 1
Size of Employer (1934)B
    1 (i.e., only myself) <1
    2–9 8
    10–99 23
    100–249 8
    250–1,000 23
    > 1,000 39
Employer Ownership Type (1913)
    For profit 31
    Non-profit 54
    City, county, district, state gov’t 11
    Federal gov’t (VHA, military, IHS) 4
Employer Regional Location (1882)B
    Northeast (CT, ME, MA, NJ, NH, NY, PA, RI, VT) 22
    Midwest (IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI) 24
    South (AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, VA, WV) 30
    West (AK, AZ, CA, CO, HI, ID, MT, NM, NV, OR, UT, WA, WY) 23
Employer Location by Population Density (1931)
    Large city (50,000 people or more) 64
    Small city (fewer than 50,000 people) 18
    Suburbs (developed areas adjacent to cities) 12
    Rural (areas outside cities generally characterized by farms, ranches, small towns, and unpopulated regions) 6
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A
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer).
B
Percents may add to more than 100 percent because respondents could select more than one answer.
C
Percents may not add up to exactly 100 percent due to rounding.
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TABLE III
Antineoplastic Drugs Administration Characteristics of Respondents
Administration Characteristics (nA) Percent
Number of years (in career) administering antineoplastic drugs to patients (2068)
    Less than one year 3
    1–5 years 18
    6–10 years 20
    11–20 years 30
    More than 20 years 29
Number of days administering antineoplastic drugs in past 7 calendar days (2043)B
    1 day 19
    2 days 19
    3 days 20
    4 days 17
    5 days 23
    6–7 days 2
Total treatmentsC administered in the past 7 calendar days (2037)
    1–2 treatments 26
    3–4 treatments 20
    5–9 treatments 17
    10–20 treatments 19
    21–40 treatments 13
    More than 40 treatments 5
Total treatmentsC compared to usual (2035)
    More treatments than usual 10
    Fewer treatments than usual 19
    About the same number of treatments as usual 71
Antineoplastic drugs administered as a liquid (2023)
    100% of treatments 75
    90–99% of treatments 14
    1–89% of treatments 7
    None of the treatments 4
Antineoplastic drugs administered as tablets/capsules (2023)B
    100% of treatments 3
    10–99% of treatments 13
    1–9% of treatments 8
    None of the treatments 75
Location(s) where antineoplastic drugs administered (2028)D
    Outpatient center/clinic 47
    Patient’s hospital room 36
    Oncologist’s office 15
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Administration Characteristics (nA) Percent
    Hospital treatment room 9
    Operating room 2
    Patient’s home 2
    Other 4
A
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer).
B
Percents may not add up to exactly 100 percent due to rounding.
C
One treatment equals one or more chemotherapy drugs administered to one patient during one therapy session.
D
Percents may add to more than 100 percent because respondents could select more than one answer.
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TABLE IV
Top 20 Antineoplastic Drugs Administered by Respondents
Antineoplastic Drug
Percent of Respondents Who
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TABLE V
Training Received and Awareness of Employer Procedures and National Guidelines for Safe Handling of 
Antineoplastic Drugs
Training/Employer Procedures nA Percent Yes
Ever received training in safe
   handling of antineoplastic drugs
2061 95
Training > 12 months ago 1950 36
Specific training courses takenB
   Oncology Nursing Society (ONS)
      Chemotherapy and Biotherapy
      course
1947 75
   ONS Safe Handling of Hazardous
      Drugs course
1947 46
   Association of Pediatric
      Hematology / Oncology Nurses
      (APHON) Chemotherapy and
      Biotherapy course
1947 11
   Other 1947 27
Employer has procedures for safe
   administration
2060 94
Familiarity with national safe
   handling guidelines PercentB familiar with guideline
Very familiar Somewhat familiar Not at all familiar
   Oncology Nursing Society (ONS)
      Safe Handling of Hazardous
      Drugs
2065 73 20 7
   Occupational Safety and Health
      Administration (OSHA)
      Guidelines for the Management
      of Antineoplastic Drugs
2067 47 43 10
   NIOSH Alert on Preventing
      Occupational Exposures to
      Antineoplastic and Other
      Hazardous Drugs in Health Care
      Settings
2059 25 41 34
   American Society of
      Health-System Pharmacists
      (ASHP) Guidelines for
      Handling Hazardous Drugs
2057 12 34 54
A
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer).
B
Percents may not add up to exactly 100 percent due to rounding.
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TABLE VI
Work Practices with Potential for Exposure
Work Practices (nA) Percent
How liquid antineoplastic drugs were most commonly received from pharmacy or drug preparation area (1910)
    I.V. tubing primed with antineoplastic drug 12
    I.V. tubing primed with non-drug containing fluid (e.g., saline) 62
    I.V. tubing not primed 21
    Not applicable (did not receive liquid chemotherapy drugs from pharmacy/drug preparation area) 5
Frequency respondent primed I.V. tubing (1910)
    Always 32
    Sometimes 7
    Never 61
How respondent primed I.V. tubing (1909)
    Respondent primed I.V. tubing with antineoplastic drug 6
    Respondent primed I.V. tubing with non-drug containing fluid (e.g., saline) 35
Crushed tablets/opened capsules (494) 13
Location where tablets crushed/capsules opened (57)B
    Bedside 33
    Clinical areas 33
    Pharmacy 33
    Other 7
Took home clothing that came in contact with antineoplastic drugs (1971)
    Yes 12
    No 77
    I don’t know 11
Activities where cross-contamination may occur
(i.e., activities done while wearing gloves that had
been used to administer antineoplastic drugs)B
    Touch I.V. pump or bed controls (1969) 61
    Touch waste basket/garbage bags (1970) 27
    Use pens/pencils (1970) 26
    Touch door knobs, cabinets, or drawers (1969) 20
    Use of computer/calculator (1970) 13
    Handle files or charts (1970) 11
    Used a non-disposable stethoscope (1969) 6
    Use of phone/cell phone or pager (1969) 3
    Eat, drink, chew gum, or smoke (1968) 2
    Use restroom (1970) <1
    Apply cosmetics (1970) <1
Put gloves back on that had been used while
administering antineoplastic drugs (1961)
1
A
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer).
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B
Percents may add to more than 100 percent because respondents could select more than one answer.
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TABLE VII
Frequency of Use of Engineering Controls, Precautionary Work Practices, and PPE While Administering 
Antineoplastic Drugs
Type of Control (nA) PercentB of Frequency of Activity
Engineering Controls Always Sometimes Never
    Use a closed-system transfer deviceC (e.g., PhaSeal) (1895) 45 8 47
    Use needleless systemC(1925) 90 5 4
    Use luer-lock fittings for all needleless systems, syringes, needles, infusion tubing, and 
pumpsC(1928)
94 3 3
Work Practices Always Sometimes Never
    Use a plastic backed absorbent pad under injection siteC(1924) 59 17 24
    Store prepared antineoplastic drugs in an area restricted to authorized personnel before 
administering them to patients (2011)
73 14 13
    Wash hands after removing gloves (2000) 92 7 1
    Replace damaged gloves immediately when contaminated (1876) 98 1 1
Personal Protective Equipment Always Sometimes Never I don’t know
    Wear chemotherapy glovesD(1972) 85 5 7 4
    Wear double chemotherapy gloves (1762) 20 20 59 <1
    Wear a nonabsorbent gown with closed front and tight cuffs (1977) 58 16 26 —E
    Wear eye or face protection (1886) 12 10 78 —
    Wear a respiratorF(1953) 2 3 95 —
    Wear shoe covers (1997) 3 3 93 —
    Wear a head cover (1995) 4 3 94 —
A
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer and excluded 
respondents where the activity was not applicable to them).
B
Percents may not add up to exactly 100 percent due to rounding.
C
This response option was only offered to respondents whose treatments included liquid chemotherapy drugs.
D
A medical glove that has been approved by FDA for use when handling antineoplastic drugs
E
Dash (—) indicates that this response option was not included in question.
F
N95, half-facepiece air-purifying respirator, or powered air-purifying respirator.
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TABLE VIII
Reasons for not Always Wearing PPE When Administering Antineoplastic Drugs













An engineering control was being
used
–G 15 22 18
(SkinH) exposure was minimal 36 42 44 33
Not part of our protocol 29 35 47 66
Not provided by employer 31 13 14 15
No one else who does this work uses
them
11 21 18 14
Too uncomfortable or difficult to use 9 15 8 6
Not readily available in work area 20 14 14 11
Cross contamination to other areas is
not a concern.
2 7 — —
Concerned about raising the patient’s
anxiety
<1 15 9
Other 18 16 13 6
A
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer).
B
Column percents add to more than 100 percent because respondents could select more than one answer.
C
A medical glove that has been approved by FDA for use when handling antineoplastic drugs.
D
Nonabsorbent gown with closed front and tight cuffs.
E
Examples included goggles and face shields.
F
Choices included N95 respirator, surgical N95 respirator, half-facepiece air-purifying respirator with chemical cartridge(s), and powered air-
purifying respirator with chemical cartridge(s).
G
Dash (—) indicates this reason was not included in question response options.
H
Response for eye/face protection and respirator was “Exposure was minimal.”
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TABLE IX
Spills of Liquid Antineoplastic Drugs During Administration: Number of Spills by Quantity, Cause of Spill, 
and Availability of Spill Response Kits
Characteristics of spills/leaks and cleanup
(nA) Percent
Spill/leak of any amount occurred in past 7 calendar days (1916) 12
   Spills or leaks of <5 ml (232)B
      No spills <5 ml 22
      1–2 spills 71
      3–5 spills 7
      >5 spills <1
   Spills or leaks of ≥5 ml (230)
      No spills ≥5 ml 91
      1–2 spills 9
Cause of spill or leakC
   attaching, injecting, or detaching from I.V. line (234) 71
   due to a bad connection (234) 33
   due to equipment malfunction (233) 22
   drawing up or expelling air from syringe (234) 19
   due to excessive pressure in vial (233) 17
Spill cleanup
   Spills not always cleaned up (190) 9
Hazardous drug spill kits were not available or didn’t know if they were (1991) 3
A
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer).
B
Percents may not add up to exactly 100 percent due to rounding.
C
Percents may add to more than 100 percent because respondents could select more than one answer.
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